

24 June 2021

**Diaceutics PLC**  
**("Diaceutics" or "the Company")**

**Multiple contracts for Inherited Retinal Disease (IRD) in APAC, EU, and US markets**

- Diaceutics is providing data analytics and implementation solutions to enable seamless commercialisation of diagnostic testing for leading global pharmaceutical companies ahead of the launch of an innovative targeted therapy for IRD
- Projects cover comprehensive mapping of IRD testing landscapes, including through the use of the Company's diagnostic commercialisation platform DXRX, and test commercialisation strategy implementation to ensure the right testing is in place at launch, supporting increased uptake of the therapy
- Contracts awarded cover key regional footprint extending to Europe, the UK, APAC & the US

Diaceutics PLC, (AIM: DXRX), the diagnostics commercialisation company for precision testing, announces it has secured four projects with two leading pharmaceutical companies to solve real-world testing hurdles for the rare disease group: Inherited Retinal Disease (IRD). IRD has, until now, been a largely untreatable disease group causing severe vision loss or even blindness, affecting around two million people worldwide. The contracts demonstrate the applicability of the DXRX diagnostic commercialisation platform outside of the Company's core area of oncology.

The services will be delivered over the course of six months in 2021 across Europe, the UK, APAC & the US. The projects are in partnership with existing pharmaceutical customers of the Company and represent an expansion of its commercial relationship into a new therapy area, in line with the Company's 'land and expand' strategy, and the increased engagement of the customers with the DXRX platform. The contracts will deliver approximately £1.0 million revenue within 2021.

**Peter Keeling, CEO and Founder of Diaceutics** says, "Diaceutics is excited to be involved with these ground-breaking therapies for IRD, giving us an opportunity to bring our extensive knowledge of personalized medicine in the oncology field to rare disease and to help patients with IRD access the best treatments available. These new project wins across a new disease area show the confidence that leading pharma companies have in Diaceutics and our considerable expansion opportunity. Through utilising the DXRX platform, alongside our advisory services, the projects can be delivered efficiently, at scale, across multiple geographies, bringing together all the segments in the precision medicine diagnostics market required to facilitate change and ensure patients get the right treatment at the right time."

Diaceutics is the first to market with a unique diagnostic commercialisation platform, DXRX, allowing stakeholders in the precision medicine market to collaborate and shape the diagnostics marketplace, in real time. Via the DXRX platform, the Group is providing both data analysis services to pharmaceutical customers, collected within the platform to highlight key opportunities and hurdles that need to be considered for testing launch, and subsequent implementation solutions, in which key testing laboratories will be engaged to ensure seamless and high-quality diagnostic testing is in place at the time of therapy launch.

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer  
Philip White, Chief Financial Officer

Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Ben Maddison  
Stewart Wallace  
Nick Adams

Tel: +44 (0)20 7710 7600

**Alma PR**

Caroline Forde  
Robyn Fisher  
Kieran Breheny

Tel: +44(0)20 3405 0205  
diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world

diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTUOSKRABUNUAR